Health Economics
Does Oncotype DX recurrence score affect management of patients with early –stage breast cancer?
Asad J, Jacobson A, Estabrook A et al.
Am J Manag Care. 2008;
American Journal of Surgery:527–529.
Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer, An Economic Analysis Based on Prognostic and Predictive Validation Studies
GH Lyman, LE Cosler, NM Kuderer, J Hornberger
Cancer. 2007;
109(6):1011-1018.
21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Breast Cancer: An Economic Analysis Including Prognostic and Predictive Information
LE Cosler, NM Kuderer, J Hornberger, GH Lyman
2006;
Abstract #6024
: Poster Discussion
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
R Simon
J Clin Oncol. 2005;
23(29):7332-7341.
Economic Analysis of Targeting Chemotherapy Using a 21-Gene RT-PCR Assay in Lymph Node-Negative, Estrogen Receptor-Positive, Early-Stage Breast Cancer
J Hornberger, LE Cosler, GH Lyman
Am J Manag Care. 2005;
11(5):313-324.
A 21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Early-Stage Breast Cancer (ESBC): An Age-Specific Economic Analysis
GH Lyman, L Cosler, J Hornberger
2004;
Abstract #2081
: Poster Discussion
Economic Analysis of Targeting Chemotherapy (CT) Using a 21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Early-Stage Breast Cancer (ESBC)
LE Cosler, J Hornberger, GH Lyman
2004;
Abstract #6036
: Poster Session
Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy
FJ Esteva, AA Sahin, M Cristofanilli, K Coombes, SJ Lee, J Baker, M Cronin, MG Walker, D Watson, S Shak, GN Hortobagyi
2003;
Abstract #17
: Oral Presentation